The GDSC data set had a total of 47 unique drugs with ten targets, including EGFR, IGF1R, HDAC1, PARP2, AURKA, and BRAF, as well as their sensitivities across 224 cancer cell lines. This evidence concerns the gene PARP2 and cancer.